VANDA PHARMACEUTICALS INC (VNDA)
Health Care · Specialty biopharmaceutical company focused on psychiatry, rare diseases, and oncology · NASDAQ
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in dermatology, rare diseases, and oncology.
What VANDA PHARMACEUTICALS INC does
Vanda Pharmaceuticals is a biopharmaceutical company developing and commercializing innovative therapies for high unmet medical needs. The company operates a commercial portfolio of four approved products: Fanapt for schizophrenia and bipolar disorder, HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY for relapsing multiple sclerosis, and NEREUS for motion-induced nausea. The pipeline includes additional formulations and indications for current products plus novel molecules targeting psychiatric disorders, dermatology, rare diseases, and oncology.
Themes: Schizophrenia and bipolar disorder treatment, Sleep disorders and circadian rhythm management, Multiple sclerosis, Dermatology and rare skin diseases, Psychiatry and anxiety disorders, Oncology and hematologic malignancies, Rare genetic diseases, Pharmacogenetics and pharmacogenomics
Fundamentals
- Price$5.28 as of 2026-08-21 close
- Market cap$319M as of 2026-08-21
- 1-year return+17.1% 2025-08-21 close $4.51 → 2026-08-21 close $5.28
- P/En/a negative earnings
- Net margin-110.0% as of 2026-08-24
- Gross margin+94.2% as of 2026-08-24
- ROE-61.4% as of 2026-08-24
- Debt / equity0.03 as of 2026-08-24
- Revenue growth (YoY)+8.2% as of 2026-08-24
- Revenue CAGR (3y)-5.3% SEC XBRL
- Beta0.66 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How VNDA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VANDA PHARMACEUTICALS INC looks technically
VANDA PHARMACEUTICALS INC (VNDA) is trading 18.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 37 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 46.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 18.8% below its 200-day average, the long-term trend line — a long-term downtrend | -18.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.61 | $5.61 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.50 | $6.50 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 4.4475. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 37 trading days ago — a "death cross", a bearish long-term signal | 37 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control | 34.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 47.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.45 to $5.59) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 72.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.94 | $9.94 |
|---|---|---|
| From the 52-week high | it is 46.9% below its 52-week high (its highest price of the past year) | -46.9% |
| Above the 52-week low | it is 23.7% above its 52-week low (its lowest price of the past year) | +23.6% |
| Below the 52-week high | it is 46.9% below its highest point of the past year | 46.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $33.44 (set on 2018-12-03) | $33.44 |
| Given back of the 52-week move | over the past year its closes ranged ($4.32 to $9.56), and it has given back almost all of its rise from last year’s low — 82% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.15 to $6.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 81.7% |
| From the all-time high | it is 84.2% below its all-time high | -84.2% |
| Nearest price level | it is trading 2.6% above a support level at $5.14 — a price it turned at five times since 2024-09-25, most recently on 2025-10-17. Since 2024-08-21 it has 8 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.6% |
| All-time low | its lowest closing price on record is $0.45 (set on 2008-12-23) | $0.45 |
| Above the all-time low | it is 1073.3% above its all-time low | +1,073% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 85% of it) | 15th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2522 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2522 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.88 and $5.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.88 – $5.19 – $5.50 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges below its 200-day average price (18.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.67× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.0% since the prior reading | -2.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Gap filled | a 8.8% gap down opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.21% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.0 percentage points (the stock lost 3.6% while the market gained 2.3%) | -6.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.1 percentage points (the stock lost 15.0% while the market gained 3.1%) | -18.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 19.4 percentage points (the stock lost 8.3% while the market gained 11.1%) | -19.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 3.4 percentage points (the stock gained 17.1% while the market gained 20.5%) | -3.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -12.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.22 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -26.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $5.16 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +2.3% |
Price levels it has turned at before
VNDA last closed at $5.28 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.14 | Support | 2.6% below the last close | turned there five times · 2024-09-25 to 2025-10-17 |
| $5.43 | Resistance | 2.8% above the last close | turned there three times · 2024-11-27 to 2026-08-05 |
| $5.58 | Resistance | 5.7% above the last close | turned there twice · 2024-11-12 to 2026-06-16 |
| $4.94 | Support | 6.4% below the last close | turned there four times · 2025-01-02 to 2026-07-29 |
| $5.71 | Resistance | 8.2% above the last close | turned there twice · 2025-10-28 to 2026-02-20 |
| $4.83 | Support | 8.5% below the last close | turned there four times · 2024-11-20 to 2025-08-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $4.45.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · Analyst price target recently CUT · lagging the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$12.19 range $5.75 – $20.00; median $11.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Heavy dependence on four commercial products for revenue generation; loss of exclusivity or generic competition could materially impact sales, particularly for HETLIOZ which faces existing and potential generic competition","Company is currently unprofitable with negative net margin of -109.99%; sustained ability to fund R&D and commercialization depends on capital availability and successful product approvals","Clinical development risks including potential failure to obtain FDA approval for pipeline candidates (BYSANTI for MDD, NEREUS for additional indications, imsidolimab for GPP) and delays in clinical trial timelines"]
What changed in the latest 10-Q
AI-assisted comparison of VNDA's 10-Q filed 2026-05-07 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- BYSANTI™ now listed as separately approved commercial product (2026-05-07 filing)
- NEREUS™ now listed as commercial product (2026-05-07 filing)
- BYSANTI™ received FDA approval for bipolar I disorder and schizophrenia (2026-05-07 filing)
- BYSANTI™ protected by data exclusivity through February 20, 2031 and patents expiring May 31, 2044 (2026-05-07 filing)
- NEREUS™ now commercially available nationwide through direct-to-consumer platform nereus.us (2026-05-07 filing)
- Fanapt® weekly TRx reached 11-year high of over 2,600 prescriptions for week ending April 24, 2026 (2026-05-07 filing)
- FDA accepted BLA for imsidolimab in GPP with PDUFA target action date of December 12, 2026 (2026-05-07 filing)
- Pivotal imsidolimab clinical study results published in April 28, 2026 issue of New England Journal of Medicine Evidence (2026-05-07 filing)
- Phase III study of VQW-765 for social anxiety disorder with results expected by end of 2026 (2026-05-07 filing)
- VQW-765 described as alpha-7 nicotinic acetylcholine receptor partial agonist (2026-05-07 filing)
- VGA-157A ASO molecule for Parkinson's disease added to pipeline (2026-05-07 filing)
- NEREUS™ listed for prevention of vomiting induced by motion (2026-05-07 filing)
- NEREUS™ development program for GLP-1 receptor agonists prevention named Thetis with results expected in 2026 (2026-05-07 filing)
- BYSANTI™ Phase III adjunctive treatment for MDD with results expected in Q1 2027 (2026-05-07 filing)
- Fanapt® LAI formulation development includes hypertension indication (2026-05-07 filing)
- Removed:
- Commercial portfolio comprised of three products reduced to statement of five products (2025-10-30 filing had three; 2026-05-07 filing has five)
- Tradipitant referred to as VLY-686 and NK-1 receptor antagonist in older filing (removed from newer filing's pipeline description with name change)
- Fanapt® described as treatment for bipolar I and schizophrenia only; hypertension removed from approved indication in older filing (2025-10-30 filing)
- Bysanti™ described as active metabolite of Fanapt® in older filing (2025-10-30 filing)
- Fanapt® LAI formulation listed for schizophrenia only in older filing (2025-10-30 filing)
- Bysanti™ in development section for acute treatment of bipolar I and schizophrenia in older filing (now approved in 2026-05-07 filing)
- Reference to FDA collaborative framework agreement dated October 1, 2025 (2025-10-30 filing only)
- References to HETLIOZ® sNDA for jet lag disorder under review (2025-10-30 filing)
- References to tradipitant clinical hold and motion sickness NDA under FDA review with December 30, 2025 PDUFA date (2025-10-30 filing)
- Reference to Bysanti™ NDA under review with February 21, 2026 PDUFA date (2025-10-30 filing)
- Commercial focus on Fanapt®, HETLIOZ®, and PONVORY® in U.S. and select international markets (2025-10-30 filing)
- Reworded:
- Commercial portfolio described as 'three products' (2025-10-30) changed to 'five products' including BYSANTI™ and NEREUS™ (2026-05-07)
- Fanapt® Q1 2025 comparison metrics: TRx up 32% and NBRx up 76% (2026-05-07) replaces Q3 2024 comparison: TRx up 35% and net sales up 31% (2025-10-30)
- VQW-765 described as 'alpha-7 nicotinic acetylcholine receptor partial agonist' (2026-05-07) versus 'nicotinic acetylcholine receptor partial agonist' (2025-10-30)
- PONVORY® indication order changed from 'psoriasis and ulcerative colitis' (2025-10-30) to 'ulcerative colitis and psoriasis' (2026-05-07)
- NEREUS™ indications expanded from motion sickness in development to FDA-approved prevention of motion-induced vomiting (2026-05-07)
- Bysanti™ development status changed from NDA under review (2025-10-30) to FDA-approved product (2026-05-07)
- Tradipitant (VLY-686) removed as separate pipeline entry; references consolidated as NEREUS™ (2026-05-07)
- Annual Report reference year changed from 2024 (2025-10-30) to 2025 (2026-05-07)
- Notes:
- Text comparison was truncated in older filing MD&A section; final accounting policy paragraph incomplete
- Accession numbers and URLs provided match stated filing dates and company (VNDA)
Risk Factors
- Added:
- Added reference to 'our ability to continue to generate United States (U.S.) sales of Fanapt® (iloperidone) oral tablets for the treatment of schizophrenia' (filed 2026-05-07)
- Added 'our ability to commercialize NEREUS™ (tradipitant) capsules for the prevention of vomiting induced by motion' (filed 2026-05-07)
- Added 'our ability to obtain approval from the FDA for NEREUS™ for the prevention of vomiting induced by GLP-1 receptor agonists and the treatment of gastroparesis' (filed 2026-05-07)
- Added 'our ability to commercialize BYSANTI™ (milsaperidone) for bipolar I disorder and schizophrenia' as separate bullet point (filed 2026-05-07)
- Added 'our ability to obtain approval from the FDA for BYSANTI™ for major depressive disorder (MDD)' as separate bullet point (filed 2026-05-07)
- Removed:
- Removed 'the impact of public health crises, epidemics, pandemics or similar events on our business and operations, including our revenue, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities' (filed 2025-10-30)
- Removed reference to 'our dependence on third-party manufacturers to manufacture Fanapt®, HETLIOZ®, HETLIOZ LQ® and PONVORY® in sufficient quantities and quality' and replaced with more general language (filed 2026-05-07)
- Removed 'our level of success in commercializing Fanapt® and HETLIOZ® in new markets' (filed 2025-10-30)
- Removed 'and Canada' from PONVORY® commercialization language (filed 2026-05-07)
- Removed combined statement about FDA approval for tradipitant for gastroparesis and motion sickness (filed 2025-10-30)
- Reworded:
- Changed 'our ability to commercialize Fanapt® (iloperidone) oral tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder' to list two separate bullet points splitting schizophrenia and bipolar I disorder treatment (filed 2026-05-07)
- Changed 'Bysanti™' to 'BYSANTI™' (capitalization/formatting change) (filed 2026-05-07)
- Changed 'Bysanti TM (milsaperidone)' combined statement to separate 'our ability to commercialize BYSANTI™' and 'our ability to obtain approval' statements (filed 2026-05-07)
- Changed 'our ability to continue to commercialize HETLIOZ®' to 'our ability to continue to generate sales of HETLIOZ®' (filed 2026-05-07)
- Changed 'our expectations regarding trends with respect to our revenues, costs, expenses, liabilities and cash' to 'our expectations regarding trends with respect to our revenues, costs, liabilities and cash' (removed 'expenses') (filed 2026-05-07)
- Changed reference to '10-K (Annual Report) for the fiscal year ended December 31, 2024' to 'December 31, 2025' (filed 2026-05-07)
- Changed reference to 'Management's Discussion and Analysis' to 'Part I, Item 2, Management's Discussion and Analysis' (filed 2026-05-07)
- Changed 'our ability to obtain approval from the FDA for tradipitant for the treatment of gastroparesis and motion sickness' to separate bullets with product name 'NEREUS™' and specific indications (filed 2026-05-07)
- Notes:
- The provided sections from the newer filing (2026-05-07) appear truncated or incomplete at the end, cutting off mid-sentence in the balance sheet section
- Only the cautionary note section and introductory material were fully provided in both filings; the actual risk factors detail section (ITEM 1A Risk Factors) is referenced but not shown in full in either excerpt
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for VNDA — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VNDA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 14,957,449
- Reported value $103,355,974
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VNDA had 7,422,856 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VNDA had 12.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9 days to cover at the same settlement.
- Reported short interest (shares) 7,422,856
- Short interest (% of shares outstanding) 12.3%
- Prior settlement (shares) 7,188,123
- Reported change 3.27%
- Days to cover (reported) 9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Otsuka Pharmaceutical (schizophrenia antipsychotics)
- Eli Lilly (bipolar disorder, antipsychotics)
- Johnson & Johnson (antipsychotics, multiple sclerosis)
- Biogen (multiple sclerosis)
- Celgene (dermatology, hematologic malignancies)
- Novartis (multiple sclerosis, psychiatry)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VNDA vs…
Frequently asked questions
What does VANDA PHARMACEUTICALS INC (VNDA) do?
Vanda Pharmaceuticals is a biopharmaceutical company developing and commercializing innovative therapies for high unmet medical needs. The company operates a commercial portfolio of four approved products: Fanapt for schizophrenia and bipolar disorder, HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY for relapsing multiple sclerosis, and NEREUS for motion-induced nausea.
What sector is VANDA PHARMACEUTICALS INC (VNDA) in?
VANDA PHARMACEUTICALS INC (VNDA) is classified in the Health Care sector. Its industry is Specialty biopharmaceutical company focused on psychiatry, rare diseases, and oncology. It trades on NASDAQ.
Who are VANDA PHARMACEUTICALS INC's (VNDA) competitors?
Notable peers of VANDA PHARMACEUTICALS INC (VNDA) include Otsuka Pharmaceutical (schizophrenia antipsychotics), Eli Lilly (bipolar disorder, antipsychotics), Johnson & Johnson (antipsychotics, multiple sclerosis), Biogen (multiple sclerosis) and Celgene (dermatology, hematologic malignancies). This peer set is informational only — not financial advice.
Is VANDA PHARMACEUTICALS INC (VNDA) overbought or oversold right now?
VANDA PHARMACEUTICALS INC (VNDA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VNDA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.